Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Secures Japanese Approval For Colorectal Cancer

This article was originally published in PharmAsia News

Executive Summary

Roche/Genentech's Avastin (bevacizumab) has become the first biologic approved to treat colorectal cancer in Japan; Roche's Japanese partner Chugai announced the approval April 18

You may also be interested in...



Roche Launches Avastin In China For Colon And Rectal Cancer Following Counterfeit Drug Incident In Shanghai

SHANGHAI - Roche announced Sept. 26 the formal launch of its anti-VEGF monoclonal antibody Avastin (bevacizumab) in China for the treatment of metastatic colon and rectal cancer. Roche will also be pursuing other cancer indications in China for the drug

Roche Launches Avastin In China For Colon And Rectal Cancer Following Counterfeit Drug Incident In Shanghai

SHANGHAI - Roche announced Sept. 26 the formal launch of its anti-VEGF monoclonal antibody Avastin (bevacizumab) in China for the treatment of metastatic colon and rectal cancer. Roche will also be pursuing other cancer indications in China for the drug

Erbitux Approval For Colorectal Cancer Sought In Japan

Genentech/Roche’s Avastin, however, could be the first biologic to gain approval for the indication in Japan.
UsernamePublicRestriction

Register

SC066128

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel